Labopharm Reports Results for First Quarter 2010
- Angelini Labopharm Joint Venture to Launch OLEPTRO(TM) in Third Quarter of This Year -
LAVAL, QC, May 5 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today reported its financial results for the first quarter 2010. All figures are in Canadian dollars unless otherwise stated.
"With our joint venture with Angelini, we are well positioned for the U.S. launch of OLEPTRO(TM) in the third quarter of this year," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "Following the launch of OLEPTRO(TM), we will have two products commercialized and generating revenue, supported by a pipeline of additional product opportunities. In particular, our INTELLITAB(TM) misuse and abuse-deterrent technology platform, which has the ability to deliver two active ingredients in a single tablet, shows considerable promise and we look forward to advancing multiple products with this platform."
Angelini Labopharm Preparing to Launch OLEPTRO(TM)
Launch preparations for OLEPTRO(TM), the Company's novel once-daily formulation of trazodone for the treatment of major depressive disorder in adults, are nearing completion. The OLEPTRO(TM) commercial strategy, including marketing and managed market access strategies, is finalized. Manufacturing of product inventory for launch is complete, supply and logistics distribution is underway, medical affairs functions deployed and sales force build-out commenced using a leading contract sales organization.
Labopharm's recently announced joint venture, Angelini Labopharm, plans to launch OLEPTRO(TM) in the U.S. with a specialty pharmaceutical sales force, whose focus will be on psychiatrists and targeted primary care physicians. A multifaceted marketing and promotional campaign is planned to support the OLEPTRO(TM) launch.
INTELLITAB(TM)
Labopharm recently announced the first product being developed using its INTELLITAB(TM) misuse and abuse-deterrent technology platform is a twice-daily formulation of oxycodone and acetaminophen (DDS-08B). More than 37 million prescriptions were written for oxycodone-acetaminophen combination products in the U.S. in 2009. The Company recently reported positive results from the pharmacokinetic study on both intact and crushed tablets. Based on these positive results, the Company is exploring opportunities to potentially establish a partnership for DDS-08B and other products for which the INTELLITAB(TM) platform may be beneficial.
Financial Results
Three-Month Period Ended March 31, 2010
Revenue from product sales for the first quarter of fiscal 2010 was $3.2 million compared with $3.8 million for the first quarter of fiscal 2009. The decrease is the result of a $0.4 million unfavourable year-over-year variance in the Euro relative to the Canadian dollar, as a significant portion of product sales are denominated in Euros. The decrease is also the result of a $0.4 million reserve for future price adjustments associated with the sampling program of one of the Company's customers. Total revenue for the first quarter of fiscal 2010 was $4.7 million compared with $5.0 million for the first quarter of fiscal 2009.
Gross margin (as a percentage of revenue from product sales) for the first quarter of fiscal 2010 was 55% compared with 63% for the first quarter of fiscal 2009. The lower gross margin in the first quarter of fiscal 2010 is the result of the unfavourable year-over-year variance in the exchange rate and the reserve for future price adjustments as discussed above, as well as the reversal of a write down of $0.2 million in the first quarter of fiscal 2009.
Licensing revenue for the first quarter of fiscal 2010 was $0.6 million and represented a portion of licensing payments received from the Company's licensing and distribution partners for its once-daily tramadol product and twice-daily tramadol-acetaminophen formulation. Licensing revenue for the first quarter of fiscal 2009 was $1.2 million. The decrease is primarily the result of the extension of the term over which the balance of the US$20 million up-front payment received from Purdue Pharma in 2005 for RYZOLT(TM) will be recognized. Royalty revenue recorded on sales of RYZOLT(TM) for the first quarter of 2010 was $0.6 million. RYZOLT(TM) was not yet launched in the U.S. in the first quarter of 2009.
Research and development expenses, before research and development tax credits, for the first quarter of fiscal 2010 were $2.5 million compared with $4.3 million for the first quarter of fiscal 2009. The decrease was primarily the result of lower clinical trial costs in the first quarter of fiscal 2010. Research and development tax credits for the first quarter of fiscal 2010 were $0.3 million, essentially unchanged from the first quarter of fiscal 2009.
Selling, general and administrative expenses for the first quarter of fiscal 2010 were $7.3 million compared with $6.7 million for the first quarter of fiscal 2009. The increase is primarily the result of expenses in the first quarter of fiscal 2010 related to preparations for the U.S. launch of OLEPTRO(TM), which were partially offset, amongst other items, by lower accruals for the Company's share of litigation costs incurred by Purdue to enforce certain of Purdue's U.S. patents related to Labopharm's once-daily tramadol product ($0.3 million for the first quarter of 2010 compared with $0.7 million for the first quarter of 2009).
Net loss for the first quarter of fiscal 2010 was $8.3 million, or $0.13 per share, compared with $8.0 million, or $0.14 per share, for the first quarter of fiscal 2009.
Cash, cash equivalents and marketable securities at March 31, 2010 were $43.3 million compared with $24.5 million at December 31, 2009. During the first quarter of fiscal 2010, the Company completed a draw down under its standby equity distribution agreement (SEDA) and an underwritten public offering of units that, combined, generated net proceeds of approximately $23.0 million. Subsequent to quarter end, Labopharm signed an agreement with Gruppo Angelini to establish a joint venture for the commercialization of OLEPTRO(TM) in the U.S. and to license OLEPTRO(TM) to the joint venture. Upon completion of the transaction, expected by the end of May 2010, Labopharm will receive an up-front payment of US$26 million such that its cash position will increase by approximately $12 million after accounting for the Company's US$14 million contribution to initially fund its proportion of the joint venture's working capital requirements.
Conference Call
Labopharm will host a conference call today (Wednesday, May 5, 2010) at 8:30 a.m. ET to discuss its first quarter fiscal 2010 results. To access the conference call by telephone, dial 647-427-7450 or 1-888-231-8191. Please connect approximately five minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until midnight on Wednesday, May 12, 2010. To access the archived conference call, dial 416-849-0833 or 1-800-642-1687 and enter the reservation number 70328455 followed by the number sign. A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.
About Labopharm Inc.
Headquartered in Laval, Canada with US offices in Princeton, New Jersey, Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 19 countries around the world, including the U.S., Canada, major European markets, South Korea and Australia. Its second product, OLEPTRO(TM), a novel formulation of trazodone for the treatment of major depressive disorder in adults, has received regulatory approval in the U.S. and is under regulatory review in Canada. Labopharm has initiated the European regulatory approval process for its third product, a twice-daily formulation of tramadol-acetaminophen. The Company also has a pipeline of follow-on products in both pre-clinical and clinical development.
About OLEPTRO(TM)
OLEPTRO(TM) (trazodone hydrochloride) Extended Release Tablets is a novel once-daily formulation of the antidepressant trazodone for the treatment of major depressive disorder (MDD) in adults.
OLEPTRO(TM) is an extended release formulation of trazodone hydrochloride, and uses CONTRAMID(R), Labopharm's clinically validated technology to control the release of active substances within oral medications, whether taken whole or scored. CONTRAMID(R), in its dry state, acts as a free-flowing, highly compressible powder. When in tablet form and wetted, it forms a long-lasting, uniform surface membrane that is ideally suited to controlled release of orally administered drugs under a broad range of in-body conditions.
Important Safety Information
Antidepressants can increase suicidal thoughts and behaviors in children, adolescents, and young adults. Suicide is a known risk of depression and some other psychiatric disorders. Patients should call their doctor right away if they experience new or worsening depression symptoms, unusual changes in behavior, or thoughts of suicide. Be especially observant within the first few months of treatment or after a change in dose. OLEPTRO(TM) is not approved for use in pediatric patients.
Warning and Precautions
Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior, or unusual change in behavior, whether or not they are taking antidepressant medications.
Patients should be monitored for clinical worsening and suicidality and for the appearance of any of the following symptoms: anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and mania. Families and caregivers should be alerted about the need to monitor patients.
The development of a potentially life-threatening serotonin syndrome, or neuroleptic malignant syndrome (NMS)-like reactions has been reported with antidepressants, and may occur with OLEPTRO(TM), particularly with concomitant use of other serotoninergic drugs.
PLEASE REFER TO THE FULL PRESCRIBING INFORMATION FOR OLEPTRO(TM) FOR ADDITIONAL WARNINGS AND PRECAUTIONS AVAILABLE AT http://www.labopharm.com/docs/022411lbl.pdf .
Adverse Reactions
The most common adverse reactions (incidence greater than or equal to five percent and twice that of placebo) are: somnolence/sedation, dizziness, constipation, blurred vision.
These are not all the possible adverse events of OLEPTRO(TM). PLEASE SEE FULL PRESCRIBING INFORMATION AVAILABLE AT http://www.labopharm.com/docs/022411lbl.pdf .
This press release contains forward-looking statements, including statements concerning the commercial potential for OLEPTRO(TM) and the ability of the Angelini Labopharm joint venture to timely launch and market OLEPTRO(TM) in the United States, statements concerning the successful completion of the partnering transaction with Gruppo Angelini, statements concerning the commercialization plan for OLEPTRO(TM), statements concerning future capital requirements of the joint venture, statements concerning the commercial potential and partnering of the INTELLITAB(TM) platform, and statements concerning the Company's pipeline of product candidates, which reflect the Company's current expectations regarding future events. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company's control. Actual events could differ materially from those projected herein and depend on a number of risks and uncertainties, including risks related to the Company's ability to complete a partnering transaction and the terms of any such collaboration, if any, risks related to the market acceptance of the Company's products and the speed of adoption by clinicians, risks related to intellectual property protection and potential infringement of third-party rights, risks related to research and development of pharmaceutical products and regulatory approvals, and risks associated with intense competition in the pharmaceutical industry generally. For additional disclosure regarding these and other risks faced by Labopharm Inc., see the disclosure contained in its public filings in the U.S. with the Securities and Exchange Commission (SEC) and in Canada with the Canadian Securities Administrators (CSA), available on the Investor Relations section of the Company's website at www.labopharm.com and on the SEC's website at www.sec.gov and on the CSA's website at www.sedar.com. Investors are cautioned not to place undue reliance on these forward-looking statements. Unless required by law, the Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events, or circumstances or otherwise.
RYZOLT(TM) is a trademark of Purdue Pharma Products L.P. OLEPTRO(TM) is a trademark of Labopharm Inc. INTELLITAB(TM) is a trademark of Labopharm Inc. CONTRAMID(R) is a registered trademark of Labopharm Inc.
Labopharm Inc.
INTERIM CONSOLIDATED BALANCE SHEETS
(Unaudited)
As at As at
March 31, December 31,
2010 2009
(thousands of Canadian dollars) $ $
-------------------------------------------------------------------------
ASSETS
Current
Cash and cash equivalents 37,355 23,650
Marketable securities 5,925 854
Accounts receivable 3,631 4,736
Research and development tax credits receivable 1,502 2,584
Income taxes receivable 12 223
Inventories 2,983 2,637
Prepaid expenses and other assets 436 701
-------------------------------------------------------------------------
Total current assets 51,844 35,385
-------------------------------------------------------------------------
Restricted investments 124 133
Long-term investment 3,035 2,885
Property, plant and equipment 8,251 8,575
Intangible assets 1,951 2,018
Future income tax assets 121 124
-------------------------------------------------------------------------
65,326 49,120
-------------------------------------------------------------------------
-------------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)
Current
Accounts payable and accrued liabilities 18,994 18,124
Current portion of deferred revenue 2,549 2,938
Current portion of obligations under capital
leases 319 309
Current portion of long-term debt 5,666 3,558
-------------------------------------------------------------------------
Total current liabilities 27,528 24,929
-------------------------------------------------------------------------
Deferred revenue 15,136 14,364
Obligations under capital leases 4,950 5,033
Long-term debt 16,453 18,939
-------------------------------------------------------------------------
Total liabilities 64,067 63,265
-------------------------------------------------------------------------
Shareholders' equity (deficiency)
Capital stock
Common shares, no par value, unlimited
authorized shares, 71,567,941 and 57,456,364
issued as at March 31, 2010 and December 31,
2009, respectively 260,231 242,316
Warrants 6,133 937
Contributed surplus 16,959 16,385
Deficit (281,882) (273,625)
Accumulated other comprehensive loss (182) (158)
-------------------------------------------------------------------------
Total shareholders' equity (deficiency) 1,259 (14,145)
-------------------------------------------------------------------------
65,326 49,120
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Labopharm Inc.
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
For the three months ended: March 31, March 31,
(thousands of Canadian dollars, 2010 2009
except share and per share amounts) $ $
-------------------------------------------------------------------------
REVENUE
Product sales 3,228 3,802
Licensing 594 1,155
Royalties 600 -
Research and development collaborations 271 -
-------------------------------------------------------------------------
4,693 4,957
-------------------------------------------------------------------------
-------------------------------------------------------------------------
EXPENSES
Cost of goods sold (excluding amortization) 1,453 1,393
Research and development expenses, net 2,165 3,983
Selling, general and administrative expenses 7,333 6,768
Financial expenses 1,097 1,014
Amortization of property, plant and equipment
and intangible assets 434 463
Interest income (168) (187)
Foreign exchange loss (gain) 635 (503)
-------------------------------------------------------------------------
12,949 12,931
-------------------------------------------------------------------------
Loss before income taxes (8,256) (7,974)
Income tax expense 1 -
-------------------------------------------------------------------------
Net loss for the period (8,257) (7,974)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Net loss per share - basic and diluted (0.13) (0.14)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average number of common shares
outstanding 64,178,485 56,826,148
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Labopharm Inc.
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
March 31, March 31,
For the three months ended: 2010 2009
(thousands of Canadian dollars) $ $
-------------------------------------------------------------------------
OPERATING ACTIVITIES
Net loss for the period (8,257) (7,974)
Items not affecting cash
Amortization of property, plant and equipment 361 422
Amortization of intangible assets 73 41
Amortization of premiums and discounts
on marketable securities 7 15
Non-cash interest income (150) -
Non-cash financial expenses 234 142
Unrealized foreign exchange loss 718 808
Stock-based compensation 574 792
-------------------------------------------------------------------------
(6,440) (5,754)
Net change in other operating items 3,613 (2,045)
-------------------------------------------------------------------------
(2,827) (7,799)
-------------------------------------------------------------------------
INVESTING ACTIVITIES
Acquisition of marketable securities (5,095) (6,568)
Proceeds from disposals of marketable securities - 4,420
Proceeds from maturities of marketable securities - 13,807
Acquisition of property, plant and equipment (96) (5)
Acquisition of intangible assets (6) (16)
-------------------------------------------------------------------------
(5,197) 11,638
-------------------------------------------------------------------------
FINANCING ACTIVITIES
Repayment of obligations under capital leases (73) (64)
Repayment of long-term debt (1) -
Proceeds from issuance of common shares 18,411 9
Proceeds from issuance of warrants 5,429 -
Payment of issuance costs of common shares
and warrants (444) -
-------------------------------------------------------------------------
23,322 (55)
-------------------------------------------------------------------------
Foreign exchange loss on cash held in
foreign currencies (1,593) (63)
-------------------------------------------------------------------------
Net change in cash and cash equivalents
during the period 13,705 3,721
Cash and cash equivalents, beginning of period 23,650 8,373
-------------------------------------------------------------------------
Cash and cash equivalents, end of period 37,355 12,094
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Supplemental cash flow information:
Interest paid 753 701
Income taxes paid (recovered) (202) 88
-------------------------------------------------------------------------
For further information: At Labopharm Inc.: Mark D'Souza, Senior Vice-President and Chief Financial Officer, Tel: (450) 686-0207; At The Equicom Group: Lawrence Chamberlain, Media and Investor Relations, Tel: (416) 815-0700 ext. 257, [email protected]; French: Joe Racanelli, Tel: (514) 844-7997, [email protected]
Share this article